Drug Trial Radar · NCT00090753
A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia
Last checked: Nov 19, 2026Latest source record: Feb 14, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,228
Actual
Start
Oct 2004
Primary completion
Dec 2009
Study completion Dec 2009
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Sep 6, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study assessed the long-term efficacy, safety, and tolerability of intravenous (iv) or subcutaneous (sc) methoxy polyethylene glycol-epoetin beta in chronic kidney disease patients with renal anemia. Eligible patients were those who were receiving stable maintenance therapy with methoxy polyethylene glycol-epoetin beta or erythropoiesis stimulating agents (ESAs) in Phase II or III clinical studies. They continued to receive methoxy polyethylene glycol-epoetin beta or comparator ESAs at the same weekly dose and by the same route of administration (sc or iv) as in the qualifying studies.
Conditions
- Anemia
Interventions
Methoxy Polyethylene Glycol-Epoetin BetaDrug
Methoxy polyethylene glycol-epoetin beta was provided as a sterile single-use injectable solution in 2-mL glass vials containing 1 mL solution or in single-use sterile pre-filled syringes (PFSs) containing 0.3 mL or 0.6 mL injectable solution. The injectable solution was available in vials with the following strengths: 50, 100, 200, 400, and 1000 μg/mL. The injectable solution was available in PFSs with the following strengths: 30, 40, 50, 60, 75, 100, 120, 150, 200, and 250 μg/0.3 mL; and 360 and 400 μg/0.6 mL.
Epoetin alfaDrug
Epoetin alfa was provided with commercial packaging in English with country-specific labels (10,000 IU, 20,000 IU).
Epoetin betaDrug
Epoetin beta was provided with commercial packaging in English with country-specific labels (50,000 IU, 100,000 IU).
Darbepoetin alfaDrug
Darbepoetin alfa was provided with commercial packaging in English with country-specific labels (vials and PFSs in various strengths).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Hemoglobin Concentration to the Last Month of Study ParticipationTime frame: Baseline to the end of the study (Up to 49 Months)
Locations
249 sites in 27 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Mobile, Alabama
Site not named
Montgomery, Alabama
Site not named
Hot Springs, Arkansas
Site not named
Covina, California
Site not named
Encino, California
Site not named
Irvine, California
Site not named
Los Alamitos, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
Monterey Park, California
Site not named
Mountain View, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
San Diego, California
Site not named
San Francisco, California
Site not named
Stanford, California
Site not named
Colorado Springs, Colorado
Site not named
Denver, Colorado
Site not named
Lakewood, Colorado
Site not named
Stamford, Connecticut
Site not named
Ocala, Florida
Site not named
Pembroke Pines, Florida
Site not named
Atlanta, Georgia
Site not named
Augusta, Georgia
Site not named
Honolulu, Hawaii
Site not named
Maywood, Illinois
Site not named
South Holland, Illinois
Site not named
Louisville, Kentucky
Site not named
Baton Rouge, Louisiana
Site not named
Shreveport, Louisiana
Site not named
Boston, Massachusetts
Site not named
Boston, Massachusetts
Site not named
Springfield, Massachusetts
Site not named
Detroit, Michigan
Site not named
Detroit, Michigan
Site not named
Kalamazoo, Michigan
Site not named
Brooklyn Center, Minnesota
Site not named
Columbus, Mississippi
Site not named
Tupelo, Mississippi
Showing 40 of 249 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.